News

Data presented by the company at the European Cystic Fibrosis Conference in Copenhagen, Denmark, highlight the significant anti-inflammatory activity discovered when each of the five candidate compounds is

Merck, which in March made its own bid for Schering, agreed to sell its recently increased stake in Schering for E89 per share. All Schering shareholders who had

Following a six-month priority review by the FDA, the expanded indication is based on phase III results that demonstrated a survival advantage by using Hycamtin in combination with

DGAT-1 inhibitors modify lipid metabolism. The lead compound in the class, BAY 74-4113, is currently in phase I clinical development. Under the terms of the agreement, Bayer will

The Company currently is conducting clinical trials for this indication. Glycopyrrolate, an anticholinergic agent, also is approved as an adjunctive therapy in the treatment of peptic ulcers. The

Sanctura XR is the once-daily formulation of Sanctura, which the company has marketed for overactive bladder for nearly two years. The data from the recently completed trial showed

These microRNAs are to be added to Rosetta’s microRNA database, providing the company with additional biomarker candidates for its diagnostic development programs. Under the terms of the agreement,

Favrille now intends to initiate a phase I/II clinical trial evaluating the safety and biologic activity of FAV-201 in patients with cutaneous T-cell lymphoma. The trial will build

The two phase III clinical studies, known as GOUT 1 and GOUT 2, are designed to compare the safety and efficacy of Puricase administered by two-hour intravenous infusion